Skip to main navigation menu Skip to main content Skip to site footer
Universidad de Panamá
##common.pageHeaderLogo.altText##
Submitted October 21, 2021
Published 2021-10-21

Artículos

Vol. 3 No. 1 (2021): Revista Colegiada de Ciencia

CHARACTERIZATION OF THE IMMUNE PRE AND POST VACCINATION WITH INFLUENZA OF THE PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS, ANTIRETROVIRAL THERAPY CLINIC OF THE REGIONAL HOSPITAL OF VERAGUAS. 2018

Cover image

Citación:
DOI: ND

Published: 2021-10-21

How to Cite

Espinoza C., A., & Peralta C., L. (2021). CHARACTERIZATION OF THE IMMUNE PRE AND POST VACCINATION WITH INFLUENZA OF THE PATIENT WITH HUMAN IMMUNODEFICIENCY VIRUS, ANTIRETROVIRAL THERAPY CLINIC OF THE REGIONAL HOSPITAL OF VERAGUAS. 2018. Revista Colegiada De Ciencia, 3(1), 30–45. Retrieved from https://revistas.up.ac.pa/index.php/revcolciencia/article/view/2454

Abstract

HIV infection is one of the main public health problems in the world. According to the (C.D.C), by 2016 there were approximately 36.7 million people with HIV in the world, and in that year there were 1.8 million new infections. Influenza affects between 10 and 20% of the world's population. HIV and influenza are epidemiological surveillance events in Panama. In this country, 40% of acute respiratory infections are caused by viruses and the third place corresponds to influenza. The influenza vaccine in risk groups is indicated in the regulations of the Panama immunization program. This study is epidemiological, retrospective and prospective analytical, because its objective is to analyze the immune response before and after vaccination with influenza in patients with human immunodeficiency virus on antiretroviral treatment. The study participants were 137 patients with HIV from the CTARV of Veraguas. We worked on Ho: There are no significant differences in the immune response before and after vaccination with influenza in patients with HIV. Demographic and immunity independent variables were compared. It was demonstrated that there is a statistical association between having CD4 + T lymphocyte values between 401-600 cells / mm 3 pre-vaccine and improving post-vaccine immunity, where having this value is a protective factor (X² = 5.829 p = 0.01). (RR = 0.68) (CI = 0.48- 0.96), in the same way, when the result of the patient's Viral Load is Indeterminate, it has a statistical association with the increase in the immune response 90 days after application of the influenza vaccine. it is a protective factor to achieve changes in the body's defense cells. (X² = 6.008 p = 0.007). 3 (RR = 0.739); only for the group studied (CI = 0.587-0.932), as established in the world literature.

Downloads

Download data is not yet available.
Content Top